

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Broncus Holding Corporation**

**壑博医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2216)**

## **VOLUNTARY ANNOUNCEMENT**

### **ENROLLMENT FOR REGISTERED CLINICAL TRIALS SUCCESSFULLY COMPLETED FOR RF-II IN CHINA**

This announcement is made by Broncus Holding Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and the potential investors of the latest updates of the business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has completed the enrollment of all subjects for the clinical trials of its self-developed core product, RF Generator + RF Ablation Catheter (“**RF-II**”), a radiofrequency ablation system that specifically targets lung cancer, in China.

Led by the First Affiliated Hospital of Guangzhou Medical University (Guangzhou Institute of Respiratory Health) and with Professor Li Shiyue as the coordinating principal investigator, the clinical trials were participated by dozens leading clinical centers across China, including Shanghai Chest Hospital and West China Hospital of Sichuan University. The RF-II ablation operations were performed smoothly and well tolerated. The safety and efficacy of RF-II were preliminarily demonstrated in patients who have already conducted follow-up evaluation.

According to the Frost & Sullivan report, there were 924,100 new lung cancer patients in China in 2020. As a minimally invasive and repeatable targeted therapy for lung tumors, radiofrequency ablation can be used alone or in combination with other therapies, potentially providing a valuable opportunity of curative and palliative treatment for most patients.

The Company’s self-developed second-generation radiofrequency ablation product is the world’s only radiofrequency ablation system dedicated to lung cancer treatment. With the assistance of AR-based optical lung diagnosis navigator LungPro, the system can quickly and accurately reach the target focus center through bronchoscope and ablate the tumors with an ablation catheter, thus offering an innovative interventional therapeutic technique for lung tumor ablation. The system is expected to provide a new way of treatment for patients with multiple primary lung cancers, postoperative recurrence, or lung cancer unsuitable for surgical treatment.

## INFORMATION ON THE COMPANY

The Company is a pioneer in the interventional pulmonology medical device market, provides innovative lung solutions in China and globally. Founded in 2012, the Company has assembled a management team with extensive experience in product development, clinical research and commercialization, and has developed into an enterprise with a China-US dual center. Through close ties with key opinion leaders in the global respiratory interventional field and the establishment of a comprehensive relationship from innovative concepts to project development and implementation, the Company has built a respiratory interventional diagnosis and treatment product pipeline comprises of 17 products and major product candidates, and owned a diversified intellectual property portfolio of 476 patents and patent applications. In addition, the Company through clinical training and market education and with its strong brand promotion and commercialization capabilities, has sales to mainstream markets around the world such as the United States, Europe, and Australia. Company's mission is to become a transformative global leader in pulmonology treatment and set its interventional pulmonology diagnosis and treatment solutions as the gold standard.

**The Company might not be able to successfully develop and commercialize RF-II. Shareholders and prospective investors are advised to exercise caution when dealing in the shares and other securities of our Company.**

By order of the Board of Directors  
**Broncus Holding Corporation**  
**ZHAO Michael Yi Wei**  
*Chairman*

Hong Kong, December 10, 2021

*As at the date of this announcement, the Board comprises Mr. ZHAN Guowei and Mr. XU Hong as executive Directors, Mr. ZHAO Michael Yi Wei as Chairman and non-executive Director, Mr. ZI Zhenjun and Mr. ZHANG Ao as non-executive Directors, and Dr. KAM Pok Man, Professor LAU Joseph Wan Yee and Dr. JI Jian as independent non-executive Directors.*